Nanomix Corporation

NNMX

US63008H2013

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 11:55:08 29/12/2023 pm IST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Nanomix Corporation Announces Chief Executive Officer Changes	CI
2023	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Boston Therapeutics, Inc. Announces Resignation of Loraine V. Upham as Chief Operating Officer

December 07, 2018 at 03:34 am IST

On November 30, 2018, Loraine V. Upham notified Boston Therapeutics, Inc. that she was resigning as Chief Operating Officer of the company effective as of the date of notification.

Latest news about Nanomix Corporation

Nanomix Corporation Announces Chief Executive Officer Changes	25/11	CI
Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	07/23/07	CI
Nanomix Corporation Auditor Raises 'Going Concern' Doubt	07/23/07	CI
Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	25/23/25	CI
Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	29/22/29	CI
Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	09/22/09	CI
Nanomix Corporation announced that it has received $0.069779 million in funding from Woodley Equipment Company Ltd.	09/22/09	CI
Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	04/22/04	CI
Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	20/22/20	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	12/22/12	CI
Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	02/22/02	CI
Nanomix Names Tadd S. Lazarus to Board of Directors	31/22/31	CI
Nanomix Corporation Appoints Tadd S. Lazarus to its Board of Directors as Independent Director	31/22/31	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	23/22/23	CI
Nanomix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Nanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of Directors	26/22/26	CI
Nanomix Corporation Announces Executive Changes	26/22/26	CI
Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	21/22/21	CI
Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel	22/22/22	CI
Nanomix Corporation Receives IVDR Certification for the eLab Analyzer	14/22/14	CI
Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples	26/22/26	CI
Nanomix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Nanomix Corporation Auditor Raises 'Going Concern' Doubt	12/22/12	CI
Nanomix Corporation Announces the Relocation of its Corporate Headquarters	30/22/30	CI

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. Its eLab System utilizes a nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results. Its S1 Assay panel is used as an aid in diagnosing infections, such as sepsis. Its CRP test results can be used to evaluate infection, tissue injury, and inflammatory disorders.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
NANOMIX CORPORATION	-.--%	4.9K
VEEVA SYSTEMS INC.	-9.49%	31.38B
PRO MEDICUS LIMITED	+25.35%	8.33B
SECTRA AB	+33.25%	4.27B
EVOLENT HEALTH, INC.	-35.85%	2.47B
VERADIGM INC.	-9.44%	1.65B
OMNICELL, INC.	-13.39%	1.5B
LUNIT INC.	-32.84%	1.07B
SIMULATIONS PLUS, INC.	+7.80%	974M
B-SOFT CO.,LTD.	-37.56%	840M